European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Kigabeq, vigabatrin, Date of authorisation: 20/09/2018, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 15:15

Human medicines European public assessment report (EPAR): Kigabeq, vigabatrin, Date of authorisation: 20/09/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Lumykras, sotorasib, Date of authorisation: 06/01/2022, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 15:05

Human medicines European public assessment report (EPAR): Lumykras, sotorasib, Date of authorisation: 06/01/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Orkambi, lumacaftor,ivacaftor, Date of authorisation: 19/11/2015, Revision: 39, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 14:45

Human medicines European public assessment report (EPAR): Orkambi, lumacaftor,ivacaftor, Date of authorisation: 19/11/2015, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 14:25

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Cometriq, cabozantinib, Date of authorisation: 21/03/2014, Revision: 32, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 14:08

Human medicines European public assessment report (EPAR): Cometriq, cabozantinib, Date of authorisation: 21/03/2014, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Ryjunea, atropine sulfate, Date of authorisation: 02/06/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 13:52

Human medicines European public assessment report (EPAR): Ryjunea, atropine sulfate, Date of authorisation: 02/06/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Voriconazole Accord, voriconazole, Date of authorisation: 16/05/2013, Revision: 23, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 13:42

Human medicines European public assessment report (EPAR): Voriconazole Accord, voriconazole, Date of authorisation: 16/05/2013, Revision: 23, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness